{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T19:24:48Z","timestamp":1774380288137,"version":"3.50.1"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","funder":[{"name":"Clinical Research Plan of SHDC","award":["SHDC2020CR1009A"],"award-info":[{"award-number":["SHDC2020CR1009A"]}]},{"name":"School of Medicine, Shanghai Jiao Tong University","award":["21XHDB08"],"award-info":[{"award-number":["21XHDB08"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To describe the clinical characteristics of secondary tumor-associated neovascularization (STN) in retinoblastoma (RB) patients and the outcomes and complications of intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) in the treatment of STN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A single-center retrospective study. Intravitreal injections of anti-VEGF were given to RB patients once STN was confirmed by fundus fluorescein angiography and performed monthly until neovascularization was resolved. Demographic characteristics, clinical characteristics, treatment outcomes, and complications after anti-VEGF therapy were recorded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>STN was detected in 12 eyes of 11 RB patients with a mean age of onset of 15 months. Eleven eyes received intra-arterial chemotherapy (IAC) (mean: six cycles, range: 2\u201311 cycles) before neovascularization onset. After receiving a mean of 4.6 (range: 1\u201318) intravitreal anti-VEGF injections, six eyes first exhibited reduced neovascularization with no relapse; five eyes first achieved resolution of neovascularization, but recurrence was observed at follow-up; and one eye received two anti-VEGF injections, but control of neovascularization was not achieved and further injections were refused. Common complications related to anti-VEGF injection included tractional retinal detachment (n = 6) and hyaloid membranes (n =5). None of the eyes needed enucleation. All the patients were alive without extraocular extension or metastases (mean follow-up 64 months, range: 37\u2013112 months).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>STN can occur in RB patients after multiple comprehensive therapies, especially IAC. Intravitreal anti-VEGF injection contributes to the resolution of neovascularization, but anti-VEGF treatment-related complications must be recognized and anticipated.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/iae.0000000000004722","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T20:00:13Z","timestamp":1762804813000},"page":"748-757","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["CLINICAL CHARACTERISTICS AND MANAGEMENT OUTCOMES OF SECONDARY TUMOR-ASSOCIATED NEOVASCULARIZATION IN RETINOBLASTOMA PATIENTS"],"prefix":"10.1097","volume":"46","author":[{"given":"Junxia","family":"Fu","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaotong","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junrui","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The 74th Army Group Hospital, Guangzhou, Guangdong, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingyi","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xunda","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China; and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20260324","first-page":"320","article-title":"Late choroidal neovascular complications in a patient treated for retinoblastoma. A case report","volume":"78","author":"Popov\u00e1","year":"2022","journal-title":"Cesk Slov Oftalmol"},{"key":"R2-20260324","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1136\/bjophthalmol-2014-305180","article-title":"Retcam fluorescein angiography findings in eyes with advanced retinoblastoma","volume":"98","author":"Kim","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"R3-20260324","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1097\/01.iae.0000225350.83931.f6","article-title":"Vitreoretinal complications of retinoblastoma treatment","volume":"26","author":"Tawansy","year":"2006","journal-title":"Retina"},{"key":"R4-20260324","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1136\/bjo.77.2.95","article-title":"Choroidoretinal neovascularisation following radon seed treatment of retinoblastoma in two patients","volume":"77","author":"Archer","year":"1993","journal-title":"Br J Ophthalmol"},{"key":"R5-20260324","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1136\/bjo.70.5.336","article-title":"Fibroblast radiosensitivity and intraocular fibrovascular proliferation following radiotherapy for bilateral retinoblastoma","volume":"70","author":"Albert","year":"1986","journal-title":"Br J Ophthalmol"},{"key":"R6-20260324","doi-asserted-by":"crossref","first-page":"423","DOI":"10.5301\/ejo.5000921","article-title":"Intravitreal chemotherapy in the management of vitreous disease in retinoblastoma","volume":"27","author":"Kiratli","year":"2017","journal-title":"Eur J Ophthalmol"},{"key":"R7-20260324","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1016\/j.ophtha.2006.06.018","article-title":"The international classification of retinoblastoma predicts chemoreduction success","volume":"113","author":"Shields","year":"2006","journal-title":"Ophthalmology"},{"key":"R8-20260324","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.ophtha.2011.09.040","article-title":"Fluorescein angiographic findings after intra-arterial chemotherapy for retinoblastoma","volume":"119","author":"Bianciotto","year":"2012","journal-title":"Ophthalmology"},{"key":"R9-20260324","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1136\/bjophthalmol-2011-301016","article-title":"Profiling safety of intravitreal injections for retinoblastoma using an anti-reflux procedure and sterilisation of the needle track","volume":"96","author":"Munier","year":"2012","journal-title":"Br J Ophthalmol"},{"key":"R10-20260324","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1097\/IAE.0000000000002339","article-title":"Intravitreal anti-vascular endothelial growth factor for the management of neovascularization in retinoblastoma after intravenous and\/or intraarterial chemotherapy: long-term outcomes in a series of 35 eyes","volume":"39","author":"Stathopoulos","year":"2019","journal-title":"Retina"},{"key":"R11-20260324","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1016\/j.ophtha.2011.03.013","article-title":"Selective ophthalmic arterial injection therapy for intraocular retinoblastoma: the long-term prognosis","volume":"118","author":"Suzuki","year":"2011","journal-title":"Ophthalmology"},{"key":"R12-20260324","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.ophtha.2014.01.026","article-title":"Intra-arterial chemotherapy for retinoblastoma in 70 eyes: outcomes based on the international classification of retinoblastoma","volume":"121","author":"Shields","year":"2014","journal-title":"Ophthalmology"},{"key":"R13-20260324","first-page":"243","article-title":"Regorafenib-related myocardial injury during atrial fibrillation","volume":"32","author":"Hsiao","year":"2016","journal-title":"Acta Cardiol Sin"},{"key":"R14-20260324","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/j.oret.2021.05.007","article-title":"Selective ophthalmic artery chemotherapy with melphalan in the management of unilateral retinoblastoma: a prospective study","volume":"5","author":"Lumbroso-Le Rouic","year":"2021","journal-title":"Ophthalmol Retina"},{"key":"R15-20260324","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S2352-4642(23)00141-4","article-title":"Intravenous versus super-selected intra-arterial chemotherapy in children with advanced unilateral retinoblastoma: an open-label, multicentre, randomised trial","volume":"7","author":"Wen","year":"2023","journal-title":"Lancet Child Adolesc Health"},{"key":"R16-20260324","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/bjophthalmol-2011-300498","article-title":"Intra-arterial chemotherapy for retinoblastoma in eyes with vitreous and\/or subretinal seeding: 2-year results","volume":"96","author":"Abramson","year":"2012","journal-title":"Br J Ophthalmol"},{"key":"R17-20260324","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.ophtha.2012.08.023","article-title":"Ophthalmic artery chemosurgery for retinoblastoma prevents new intraocular tumors","volume":"120","author":"Abramson","year":"2013","journal-title":"Ophthalmology"},{"key":"R18-20260324","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1136\/neurintsurg-2019-014909","article-title":"Intra-arterial chemotherapy for retinoblastoma: an updated systematic review and meta-analysis","volume":"11","author":"Ravindran","year":"2019","journal-title":"J Neurointerv Surg"},{"key":"R19-20260324","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1097\/IAE.0b013e318203c101","article-title":"Occurrence of sectoral choroidal occlusive vasculopathy and retinal arteriolar embolization after superselective ophthalmic artery chemotherapy for advanced intraocular retinoblastoma","volume":"31","author":"Munier","year":"2011","journal-title":"Retina"},{"key":"R20-20260324","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/BF00598619","article-title":"Visual toxicity following intra-arterial chemotherapy with hydroxyethyl-CNU in patients with malignant gliomas. A prospective study with statistical analysis","volume":"33","author":"Defer","year":"1991","journal-title":"Neuroradiology"},{"key":"R21-20260324","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1002\/cncr.25850","article-title":"Isolated limb perfusion for unresectable extremity sarcoma: results of 2 single-institution phase 2 trials","volume":"117","author":"Wray","year":"2011","journal-title":"Cancer"},{"key":"R22-20260324","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.jamcollsurg.2008.12.019","article-title":"A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US","volume":"208","author":"Beasley","year":"2009","journal-title":"J Am Coll Surg"},{"key":"R23-20260324","first-page":"638","article-title":"Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases","volume":"72","author":"Pe'er","year":"1995","journal-title":"Lab Invest"},{"key":"R24-20260324","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/MPH.0b013e3181923cc5","article-title":"Some clinical findings at presentation can predict high-risk pathology features in unilateral retinoblastoma","volume":"31","author":"Chantada","year":"2009","journal-title":"J Pediatr Hematol Oncol"},{"key":"R25-20260324","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.5858\/133.8.1210","article-title":"Histopathologic risk factors in retinoblastoma in India","volume":"133","author":"Gupta","year":"2009","journal-title":"Arch Pathol Lab Med"},{"key":"R26-20260324","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/pbc.23239","article-title":"Clinical predictors of high risk histopathology in retinoblastoma","volume":"58","author":"Kashyap","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"R27-20260324","doi-asserted-by":"crossref","first-page":"1144951","DOI":"10.3389\/fonc.2023.1144951","article-title":"PDGF, NGF, and EGF as main contributors to tumorigenesis in high-risk retinoblastoma","volume":"13","author":"Al-Ghazzawi","year":"2023","journal-title":"Front Oncol"},{"key":"R28-20260324","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.5858\/arpa.2014-0262-OA","article-title":"Expression of angiogenic factors in invasive retinoblastoma tumors is associated with increase in tumor cells expressing stem cell marker Sox2","volume":"139","author":"Garcia","year":"2015","journal-title":"Arch Pathol Lab Med"},{"key":"R29-20260324","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.3390\/jcm10235496","article-title":"Retinal diseases regulated by hypoxia-basic and clinical perspectives: a comprehensive review","volume":"10","author":"Shinojima","year":"2021","journal-title":"J Clin Med"},{"key":"R30-20260324","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1167\/iovs.17-22785","article-title":"Leucine-rich \u03b1-2-Glycoprotein-1 (LRG-1) expression in retinoblastoma","volume":"59","author":"Amer","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004722","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T16:07:13Z","timestamp":1774368433000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004722"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000004722","relation":{},"ISSN":["0275-004X","1539-2864"],"issn-type":[{"value":"0275-004X","type":"print"},{"value":"1539-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]}}}